As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.
16 Analysts have issued a Capricor Therapeutics, Inc. forecast:
16 Analysts have issued a Capricor Therapeutics, Inc. forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 11 11 |
52%
52%
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -85 -85 |
145%
145%
|
|
| EBIT (Operating Income) EBIT | -87 -87 |
140%
140%
|
|
| Net Profit | -82 -82 |
140%
140%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.
| Head office | United States |
| CEO | Linda Marbán |
| Employees | 160 |
| Founded | 1996 |
| Website | capricor.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


